|
“Cancer is not one disease but many diseases. We call them all ‘cancer’ because they share a fundamental feature: the abnormal growth of cells.” |
|
โThe Emperor of All Maladies byย Siddhartha Mukherjee |
๐๐ก๐ ๐๐๐ ๐๐ซ๐ฎ๐ ๐ ๐ซ๐๐ฏ๐๐ฒ๐๐ซ๐ ๐ข๐ฌ ๐๐ซ๐จ๐ฐ๐๐๐
Since 1995, when the FDA approved riluzole for amyotrophic lateral sclerosis (ALS) โ offering a median survival extension measured in weeks โ more than 60 compounds have advanced to clinical evaluation, with the overwhelming majority failing to demonstrate efficacy.(p1) It is worth distinguishing, within that graveyard, between uninformative โfailedโ trials that lacked biomarkers and left […]
The choroid plexus (ChP): hydrodynamic bottleneck and ground zero for Alzheimer’s
The choroid plexus (ChP): hydrodynamic bottleneck and ground zero for Alzheimer’s diseaseย https://ejournals.uni-muenster.de/fnp/article/view/9368/9664 The Institute has advanced a Dual Sequestration Hypothesis (DSH) related to the protein signatures prevalent in Alzheimer’s disease.ย If the DSH is correct, the ChP should enlarge and become the sentinel hydrodynamic bottleneck as synthetic particles and their protein sequestrants accumulate. This […]
Accelerating the Orphan GPCR Pipeline: GPR149 as a Case Study in Dual-Domain Target Validation
https://doi.org/10.1016/j.drudis.2026.104678ย Free download of the article using this link until June 16:ย https://authors.elsevier.com/a/1n0uP4r9Rkz1l6 Highlights New four-pillar framework accelerates deorphanization of dark GPCR targets. (77 chars) GPR149 structural analysis identifies non-canonical ERY and DPxxF motifs. (76 chars) Path-agnostic screening bypasses traditional Gi/oย signaling limitations. (75 chars) Integrated CNS and metabolic mapping reveals GPR149โฒs dual-domain value. (76 chars) […]
In the 1950s, my physicist father met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory.
In the 1950s, my physicist father, Eugene Guth, met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory. Einstein, it turned out, was more interested in the philosophy of physics than the math, a topic equally of interest to my dad.ย See https://michaelguth.com/family/HistoryofPhysicsbyEugeneGuth.htm Mathematics and philosophy of physics have relevance […]
Authority, Long-term Reach, and “Save” Signals
New evidence provides a stronger link between chronic anxiety and future neurocognitive decline, demanding a re-evaluation of how we approach dementia prevention in clinical practice. A major updated meta-analysis, now available in the Journal of Clinical Medicine, confirms that anxiety is significantly associated with an increased risk of all-cause dementia. This extensive study, spanning nine […]
Cancer is a syndrome of diseases
Posted by Michael A. S. Guth on August 15th, 2026
If you had a neuroendocrine tumor, would you be willing to try a radioactive drug as a small part of your treatment?
Posted by Michael A. S. Guth on August 11th, 2026
If you had a ๐ง๐๐ฎ๐ซ๐จ๐๐ง๐๐จ๐๐ซ๐ข๐ง๐ ๐ญ๐ฎ๐ฆ๐จ๐ซ ๐ข๐ง ๐ฒ๐จ๐ฎ๐ซ ๐ฌ๐ญ๐จ๐ฆ๐๐๐ก, ๐ฌ๐ฆ๐๐ฅ๐ฅ ๐ข๐ง๐ญ๐๐ฌ๐ญ๐ข๐ง๐, ๐๐ฉ๐ฉ๐๐ง๐๐ข๐ฑ, ๐๐จ๐ฅ๐จ๐ง, ๐ฉ๐๐ง๐๐ซ๐๐๐ฌ, ๐ฅ๐ฎ๐ง๐ ๐ฌ, ๐๐๐ซ๐๐ง๐๐ฅ ๐ ๐ฅ๐๐ง๐๐ฌ, ๐ญ๐ก๐ฒ๐ซ๐จ๐ข๐, ๐ฉ๐ข๐ญ๐ฎ๐ข๐ญ๐๐ซ๐ฒ, ๐ซ๐๐๐ญ๐ฎ๐ฆ, ๐๐ซ๐๐๐ฌ๐ญ, ๐จ๐ซ ๐ฉ๐ซ๐จ๐ฌ๐ญ๐๐ญ๐, ๐ฐ๐จ๐ฎ๐ฅ๐ ๐ฒ๐จ๐ฎ ๐ฐ๐๐ง๐ญ ๐ญ๐จ ๐ญ๐ซ๐ฒ ๐ ๐ซ๐๐๐ข๐จ๐๐๐ญ๐ข๐ฏ๐ ๐๐ซ๐ฎ๐ ย as (a small) part of the treatment?
The emerging clinical dataset highlights excellent short-term tolerability for 212Pb-TAT, with adverse events primarily consisting of low-grade nausea, fatigue, and manageable lymphocytopenia.3,17,18,21 However, long-term toxicities are typically delayed and insidious. The pituitary gland is the prime organ at risk due to high SSTR2 expression in the anterior pituitary, with diagnostic [68Ga]Ga-DOTATATE PET/CT consistently showing uptake in the sella turcica. While beta-PRRT carries an โ 8% risk of delayed pituitary dysfunction over 5โ10 years,4 the higher relative biological effectiveness (RBE) of alpha particles could substantially increase this risk. Preclinical models provide direct evidence of alpha particle-induced endocrine disruption.
Long-term radiotoxicity studies with [212Pb]Pb-TCMC (1,4,7,10-tetrakis(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane)-rituximab in murine models of Non-Hodgkin lymphoma demonstrate that renal toxicity may emerge months after treatment. Quelven et al (2025) observed significant increases in urea and creatinine at 4โ6 months post-therapy, with histopathologically confirmed renal damage.26 Notably, toxicity was reduced by optimizing specific activity, suggesting that careful dose optimization and extended follow-up are essential for 212Pb-based therapies.
Therapy-related myeloid neoplasms/acute myeloid leukemia (t-MDS/AML) occur in 2%โ3% of beta-PRRT patients with latency of several years7โa risk plausibly heightened with alpha-emitters due to potent energy deposition in hematopoietic stem cells.4,5 The bystander effect expands the potential โat-riskโ tissue volume beyond cells with direct radiopharmaceutical uptake, meaning healthy cells adjacent to targeted cells may suffer collateral damage via intercellular signaling.14
First-in-human phase 0 studies of prostate-specific membrane antigen (PSMA)-targeted 212Pb ligands confirm safety and feasibility in heavily pretreated populations. While therapeutic efficacy was not expected at microdose levels, the favorable safety profile supports further dose-escalation trials.
An unexpected safety advantage of 212Pb-labeled radiopharmaceuticals is their inherent antimicrobial potency. Studies with [212Pb]Pb-dotamtate demonstrated a โฅ 6-log reduction in colony-forming units for microorganisms, including S. aureus and C. albicans, within 6 hours of exposure, at absorbed doses below 1.01 kGy.28 This โself-sterilizingโ property adds an additional layer of pharmaceutical safety, reducing the risk of microbial contamination in drug product vials.
Activate to view larger image,
๐๐๐ซ๐ ๐๐ญ๐ข๐ง๐ ๐๐๐-๐๐ ๐ข๐ง ๐๐๐: Causal Driver, Toxic Passenger, or Loss-of-Function Crisis?
Posted by Michael A. S. Guth on August 10th, 2026
https://authors.elsevier.com/a/1nYxN4r9Rkz1wZ
TDP-43 is the most common neuropathological signature of ALS and one of the two most common pathologies in frontotemporal dementia (FTD), alongside fused in sarcoma (FUS) proteinopathy.10,11 Its cytoplasmic mislocalization and aggregation are observed in approximately 97% of all ALS cases, both sporadic and familial, with the notable exceptions of SOD1-linked disease and FUS-associated ALS.11 This near-universality makes it a compelling therapeutic target. It also makes the absence of any approved TDP-43-directed therapy nearly two decades after its identification as an ALS/FTD disease protein in 2006 a central puzzle of ALS drug development.10 ALS clinical trials as a field span more than three decades, dating to the 1993 discovery of SOD1 mutations, but dedicated TDP-43-directed therapeutic development is a more recent, roughly 20-year effort dating from Neumann et al.โs 2006 report.10
The unresolved mechanistic question is whether TDP-43 aggregation is a cause of motor neuron death, a consequence of upstream insults (such as glutamate excitotoxicity, mitochondrial dysfunction, or RNA metabolism dysregulation), orโcriticallyโa downstream epiphenomenon that obscures a primary loss-of-function pathology.12 Riluzole centered on glutamate; edaravone targeted oxidative stress. Whether these modest effects reflect incomplete target engagement or the fundamental irrelevance of their targets to disease causation remains unanswered; for riluzole specifically, โtarget engagementโ is itself difficult to define precisely given the drugโs several proposed mechanisms and the absence of a settled consensus on which one is primarily responsible for its clinical effect. A successful CTx1000 program would, for the first time, provide empirical evidence that TDP-43 proteinopathy is causally necessaryโnot merely correlativeโfor motor neuron loss in sporadic ALS, representing a genuine paradigm shift in the fieldโs understanding of disease mechanism.
Two Pathologies, One Protein. The field has increasingly recognized that TDP-43 dysfunction operates through two parallel mechanisms. The cytoplasmic gain-of-function toxicity that CTx1000 directly targets is only half the story. Equally consequential is the loss of normal nuclear TDP-43 function, particularly its role in RNA splicing regulation: nuclear depletion of TDP-43 leads to the inclusion of unannotated or cryptic exons in transcripts encoding key neuronal survival regulators, including STMN2 and UNC13A.13,14 This splicing dysregulation, observed in patient postmortem tissue, may be a driver of neurodegeneration that is at least as proximal as cytoplasmic aggregation itself, and antisense oligonucleotides (ASOs) designed to correct UNC13A cryptic splicing have already been shown to rescue synaptic function in TDP-43-depleted human neurons,ย providing independent, complementary evidence for the causal importance of TDP-43 loss-of-function.14,15 A therapy that clears cytoplasmic aggregates without restoring nuclear splicing functionโor, worse, one that inadvertently exacerbates nuclear depletionโmight produce incomplete or even detrimental clinical outcomes. CTx1000โs 14-3-3ฮธ/degron design was purposely engineered to preserve functional nuclear TDP-43 while removing the harmful cytoplasmic form. However, the underlying mechanistic selectivity has so far been demonstrated as preferential rather than absoluteโthe fusion protein shows higher affinity for pathological versus physiological TDP-43 rather than binding pathological TDP-43 exclusivelyโand its behavior in aged human neurons remains an open empirical question.9
Google Scholar Publications Michael A. S. Guth
Posted by Michael A. S. Guth on August 9th, 2026
- An Independent Review of Camrelizumab-Rivoceranib Combination Therapy for the Treatment of Hepatocellular Carcinoma and Rivoceranib for Gastric Cancer. Biomedical Journal of Sci & Tech Res, 58(2) (Aug 2024). https://biomedres.us/fulltexts/BJSTR.MS.ID.009118.php
- Surgical Implantation of Autologous Dopamine Neuron Progenitor Cells (DANPCs) Into the Putamen of Patients with Parkinsonโs Disease, Surgical Medicine Open Access Journal, (December 2024),
- Compounded Tirzepatide Therapy for Weight Loss: A Health Economics & Outcomes Research (HEOR) Analysis. Int J Pharm Compd. 2025 Jan-Feb;29(1):52-63. PMID: 39921911. (January 2025).
- Stem Cell Exhaustion as a Hallmark of Aging, invited article, Cell Research and Regenerative Medicine, 1(2), (April 2025).
- Mitochondrial Dysfunction, a Hallmark of Aging: Mechanisms, Consequences, and Therapeutic Strategies, Cell Research and Regenerative Medicine, invited article, (April 2025).
- Nicotinamide Riboside and NAD+ Decline: Hype vs. Evidence. invited article, Novel Techniques in Nutrition and Food Science 8 (4). (August 2025). http://dx.doi.org/10.31031/ntnf.2025.08.000692.
- Accelerating the Orphan GPCR Pipeline: GPR149 as a Case Study in Dual-Domain Target Validation, invited article, Drug Discovery Today (a PubMed-indexed journal), 2026 May;31(3):104678. doi: 10.1016/j.drudis.2026.104678. Epub 2026 Apr 20. PMID: 42019879 April 2026.
- Alzheimer’s disease in theย Plasticeneera: a clinicopathological update on the dual sequestration of amyloid and tau as hijacked innate immune responses. Free Neuropathol. 2026 Jun 22;7:14. doi: 10.17879/freeneuropathology-2026-9368. PMID: 42344202; PMCID: PMC13288216. June 2026.
- Implementing Pb-212-Targeted Alpha Therapy: A Safety-First Theranostic Framework for Clinical Practice, invited article Clinical Nuclear Medicine Open (a PubMed-indexed journal), Implementing 212 Pb-Targeted Alpha Therapy: A… : Clinical Nuclear Medicine Open, July 2026, slated to appear in the September 2026 issue.
- The Amyloid Trap: How Financial Entrenchment, Shareholder Pressure, and Institutional Inertia Kept Alzheimerโs Drug Development Locked in Falsified Mechanisms, forthcoming Free Neuropathology (a PubMed-indexed journal), August 2026.
- Targeting TDP-43 in ALS: Regulatory Hurdles, Trial Design Deficiencies, and the Causal Evidence Gap for CTX1000, invited article, forthcoming Drug Discovery Today (a PubMed-indexed journal), July 2026. https://authors.elsevier.com/a/1nYxN4r9Rkz1wZ
- The Adjuvant Paradox: Immunogenic Cell Death, T-Cell Exhaustion, and the Limits of Somatostatin Receptor-Targeted ฮฑ-Therapy in Neuroendocrine Tumors, in production by Hastings Case Report (a PubMed-indexed journal) June 2026.ย
“Some Uses and Limitations of Fuzzy Logic in Artificial Intelligence Algorithms for Reactor Control.”ย Nuclear Engineering and Design, 113 (1989) 99-109. (AI/ML foundational research in high-risk systems)
“A Probabilistic Foundation for Vagueness and Imprecision in Fault Tree Analysis.”ย IEEE Transactions on Reliability, 40:5 (December 1991) 563-571.
“Translating Higher-Order Decisions Into Flight Plans.”ย Journal of Operations Research, January 1994.
“Prosecution of Obscenity on Computer Networks.”ย Jurimetrics Journalย 37:235 (1996).
“Clinical Incentives and Business Disincentives for Delayed Aging.”ย Clinical Business Excellence, December 2013.
“The Use of Clomiphene Citrate in Male Hormone Replacement Therapy.”ย Acta Medica International, 2015; 2(1):14-18. (First medical journal article on clomiphene as hormone replacement for men)
“Compounded Testosterone Troches to Optimize Health and the Testosterone Controversy.”ย International Journal of Pharmaceutical Compounding, 2015; 19(3):195-203. (First article in hormone replacement literature to mention testosterone troches)
“Compounding Pharmacies’ Potential to Create Graft Storage Solutions For Bypass Surgeries.”ย International Journal of Pharmaceutical Compounding, 2015; 19(5):373-379.
“Bioidentical Hormone Replacement Therapy for Men in the Primary Care Setting.”ย Quality in Primary Care, November 2016, 24(5):222-224.
โAn Expert System for Curtailing Power,โ West Virginia Journal of Law and Technology (March 1999), available on-line at www.wvjolt.wvu.edu.
โProsecution of Obscenity on Computer Networks,โ 37 Jurimetrics J. 235 (1996).
“A Decision Support System on the Debris Land Disposal Restrictions under the Resource Conservation and Recovery Act,” (with J. Crutcher), Waste Management, June 1996.
Book entitled Speculative Behavior and the Operation of Competitive Markets Under Uncertainty (Avebury, Ashgate Publishing Group, England, December 1994).
“Development of an Expert System:ย Translating Higher-Order Decisions Into Flight Plans,”
Journal of Operations Research, January 1994.
“Bang-Bang Production of Exhaustible Resources,” (with D. Reister), International Review of Economics and Business, 39:1 (January 1992) 5-20.
“A Probabilistic Foundation for Vagueness and Imprecision in Fault Tree Analysis,” IEEE Transactions on Reliability, 40:5 (December 1991) 563-571.
“A Reexamination of Arbitrage Pricing Theory (APT) under Common Knowledge Beliefs,” (with G. Philippatos), International Rev. of Economics and Business, 36:8 (August 1989) 729-746.
“Intrinsic Uncertainty and Common Knowledge Priors in Financial Economics,” Journal of Financial Research, 22:4 (Winter 1989) 269-283.
“Practical Considerations for Developing Maintenance on Instruments,” IEEE Transactions on Reliability, 38:2 (June 1989) 253-264.
“Profitable Destabilizing Speculation:ย A Review With Some Modern Uncertainty Theory Insights,” International Review of Economics and Business, 35:6 (June 1988) 523-538.
“An Expert System Design Incorporating Fuzzy Logic for Diagnosing Heat Imbalances in a Nuclear Power Plant,” in John Benoit and H. James Antonisse, Eds., Expert Systems in Government Symposium, (Washington, D.C.:ย IEEE Press, 1987).ย Reprinted in extended form under title “Some Uses and Limitations of Fuzzy Logic in Artificial Intelligence Algorithms for Reactor Control” in Nuclear Engineering and Design, 113 (1989) 99-109.
“Uncertainty Analysis of Rule-Based Expert Systems with Dempster-Shafer Mass Assignments,” International Journal of Intelligent Systems, 3 (June 1988) 123-139.
“Incorporating ‘Fuzzy’ Data and Logical Relations into the Design of Expert Systems for Nuclear Reactors,” in Artificial Intelligence and Other Innovative Computer Applications in the Nuclear Industry, Ed. Catherine Majumdar, (New York:ย Plenum Press, 1988).
“Functional Form in Finished Good Inventory Investment,” Journal of Money, Credit, and Banking, 19 (August 1987) 396-401.
“Solar Hydrogen Small User Market Penetration:ย Economic Potential and Barriers,” International Journal of Hydrogen Energy, 11 (1986) 1-19.
“United States Hydrogen Consumption Trends Through the Year 2000,” International Journal of Hydrogen Energy, 10:1 (1985) 1-10.
“Solar Thermal Technology Impact Assessment on Imported Petroleum,” Energy Systems and Policy, 8:1 (January 1984) 67-89.
ย
MAGAZINE ARTICLES
โWeather Research for Trading Profits,โ (with Gary Lackmann, Scott E. Kennedy, and K. Wyat Appel), The Risk Desk, May 2002.
โResearch Agenda for 2002:ย Part III,โ The Risk Desk, April 2002.
โEmpirical Tests of May Spot Prices:ย A Special Trading Strategy Analysis,โ The Desk (March 15, 2002).
โResearch Agenda for 2002:ย Part II,โ The Risk Desk, March 2002.
โResearch Agenda for 2002:ย Part I,โ The Risk Desk, Feb. 2002.
โFutures, Futures, and TVA,โ The Desk (Feb. 22, 2002).
โBenefits of Accurately Determining Electricity Price Distributions: Better Risk Metrics, Beating the Market on Trades,โ The Risk Desk, Jan. 2002.
โThe Mythical Logic of Power Futures Markets,โ The Risk Desk, Dec. 2001.
โElectricity Demand in the Digital Economy,โ Energy and Power Risk Management, Nov. 2001.
โAvailability Guarantees on Combined-Cycle Plants,โ Power Engineering, March 2001.
โBlowing Hot and Cold,โ Energy and Power Risk Management, April 2000.
โAnticipating Antitrust Concerns Nets M&A Success,โ Electric, Light, and Power, October 1999; (article discusses the Federal Energy Regulatory Commissionโs delivered price test).
โThe Role of a Risk Manager,โ Energy and Power Risk Management, March 1999; (article discusses the need for financial controls managers to be independent of the head of the trading floor).
“How to Evaluate Electricity Options: Avoid Relying on Black-Scholes,” Electric, Light, and Power, December 1998.
“Value-at-Risk (VAR) is Not Enough,” Energy and Power Risk Management, Nov. 1998; (article enumerates various problems with using VAR and other risk management practices).
“Game Theory, Game Practice,” Energy and Power Risk Management, Oct. 1998; (article discusses gaming behavior leading to speculative bubbles in electricity markets).
“Expert Systems for Non-Experts,” Energy and Power Risk Management, Sept. 1998; (article discusses an expert system to explain the legal consequences of curtailing power under various electricity sales contracts).
“Drive to Compete May Result in Unexpected Legal Implications,” Energy Marketing, July-Aug. 1998, pp.8-15.ย Article based on talk “Jurassic Spark:ย Business Torts, Crimes, and Dinosaurs in Competitive Electricity Markets.”
“Exercise By Numbers,” Risk, 5:2 (February 1992) 33-37.
“๐๐ ๐ฒ๐จ๐ฎ ๐๐ซ๐ ๐ฐ๐จ๐ซ๐ค๐ข๐ง๐ ๐จ๐ง ๐ฌ๐จ๐ฆ๐๐ญ๐ก๐ข๐ง๐ ๐ญ๐ก๐๐ญ ๐ฒ๐จ๐ฎ ๐ซ๐๐๐ฅ๐ฅ๐ฒ ๐๐๐ซ๐ ๐๐๐จ๐ฎ๐ญ, ๐ฒ๐จ๐ฎ ๐๐จ๐งโ๐ญ ๐ก๐๐ฏ๐ ๐ญ๐จ ๐๐ ๐ฉ๐ฎ๐ฌ๐ก๐๐. ๐๐ก๐ ๐ฏ๐ข๐ฌ๐ข๐จ๐ง ๐ฉ๐ฎ๐ฅ๐ฅ๐ฌ ๐ฒ๐จ๐ฎ.” โ๐๐ญ๐๐ฏ๐ ๐๐จ๐๐ฌ
Posted by Michael A. S. Guth on August 6th, 2026
True momentum does not come from forced oversight, rigid deadlines, or endless motivation hacks. When a mission genuinely resonates with your core values and intellect, the dynamic shifts entirely from external pressure to internal gravity. The destination itself acts as an irresistible force, aligning your energy naturally toward the outcome.
In complex fields like health outcomes research, market access, and life sciences strategy, this distinction becomes glaringly obvious. Navigating the hurdles of value demonstration, HTA submissions, or generating robust real-world evidence demands immense perseverance. When teams are merely complying with a mandate, every milestone feels like an uphill battle against friction and fatigue.
Conversely, when everyone involved deeply understands the human and economic impact of closing evidence gaps, the day-to-day work transforms. Obstacles stop being roadblocks and turn into puzzles waiting to be solved. Curiosity replaces obligation, and cross-functional collaboration flows without the constant need for administrative orchestration.
Cultivating this kind of pull requires leaders to connect the dots clearly between high-level strategy and tangible patient outcomes. People need to see the real-world difference their models, analyses, and publications make in the lives of patients suffering from rare diseases, oncology challenges, or chronic conditions. Purpose must be visible and palpable in every project brief.
Ultimately, the most enduring breakthroughs in biotech and healthcare do not stem from grueling push-cycles. They happen when brilliant minds are anchored to a compelling vision that makes the next logical step feel inevitable. Build environments where the destination is so meaningful that people naturally run toward it.
Targeted Alpha Therapy as Cannonballs
Posted by Michael A. S. Guth on August 6th, 2026
The landscape of peptide receptor radionuclide therapy (PRRT) is shifting toward 212Pb, which has demonstrated ORRs in patients refractory to standard beta-emitters.1,2 First-in-human studies confirm the feasibility and tolerability of this approach, with disease stabilization observed even in heavily pretreated populations.3 The potent cytotoxicity of alpha particles results from dense ionization tracks, causing irreparable DNA damage.4,5
While effective against resistant clones, this mechanism increases the risk to the pituitary gland, which expresses the constitutively active somatostatin receptor subtype 2 (SSTR2). Long-term follow-up after beta-PRRT has established baseline rates of delayed hypopituitarism (โ8%) and therapy-related myeloid neoplasms (2%โ3%).6,7 Transitioning to routine practice requires a structured protocolโone that translates radiobiological principles into a practical roadmap. The protocol must embed risk mitigation at every step of the clinical pathwayโfrom patient selection to lifetime follow-up.
Recent advances in quantitative SPECT imaging and dosimetry for 203Pb/212Pb now make personalized treatment planning clinically feasible.8โ10 As the radiotheranostic field evolves toward radiohybrid systems and antibody-mimetic proteins with enhanced specificity and faster clearance, 212Pb is positioned as a primary successor for patients who fail beta-emitting therapies.11 Comprehensive reviews of the radiotheranostic landscape confirm that this principle is now gaining recognition across the field.12
For these patients and others who are refractory to standard-of-care treatment, this article provides a practice-oriented roadmap that translates complex radiobiological principles into a visually guided, step-by-step operational plan that can be implemented immediately in the multidisciplinary radio-oncology medical center. This plan or framework is built on 4 actionable pillarsโadvanced biomarker selection, personalized dosimetry, prospective safety monitoring, and registry scienceโand culminates in a consolidated Clinical Decision Pathway (see Table 2, infra).
Our objective is to equip clinicians with the specific tools and protocols needed to harness the formidable power of targeted alpha therapy (TAT) while unequivocally prioritizing patient safety.
The fundamental biophysical mechanism that confers this agentโs high potencyโalpha particle-induced DNA damageโis illustrated in Figure 1. Because an alpha particle is actually a helium nucleus (2 protons and 2 neutrons), it is much heavier than a lone proton, which is why it acts like a โcannonball,โ causing that clustered, irreparable double-strand break, as illustratesโโโโโโd in Figure 1. High-resolution conceptual modeling illustrates the โbulkierโ clustered damage characteristic of alpha radiation compared with the single-strand nicks typically associated with beta particles.
“๐๐ง๐๐จ๐ซ๐ฆ๐๐ ๐๐จ๐ง๐ฌ๐๐ง๐ญ ๐ข๐ฌ ๐ง๐จ๐ญ ๐ฃ๐ฎ๐ฌ๐ญ ๐ญ๐ก๐ ๐ฌ๐ข๐ ๐ง๐ข๐ง๐ ๐จ๐ ๐ ๐๐จ๐ซ๐ฆ. ๐๐ง๐๐จ๐ซ๐ฆ๐๐ ๐๐จ๐ง๐ฌ๐๐ง๐ญ ๐ข๐ฌ ๐๐๐จ๐ฎ๐ญ ๐ ๐ญ๐ก๐จ๐ซ๐จ๐ฎ๐ ๐ก ๐ฉ๐ซ๐จ๐๐๐ฌ๐ฌ ๐จ๐ ๐๐จ๐ฆ๐ฆ๐ฎ๐ง๐ข๐๐๐ญ๐ข๐จ๐ง ๐๐๐ญ๐ฐ๐๐๐ง ๐ฉ๐๐ญ๐ข๐๐ง๐ญ ๐๐ง๐ ๐ฉ๐ซ๐จ๐ฏ๐ข๐๐๐ซ.”
Posted by Michael A. S. Guth on August 5th, 2026
“๐๐ง๐๐จ๐ซ๐ฆ๐๐ ๐๐จ๐ง๐ฌ๐๐ง๐ญ ๐ข๐ฌ ๐ง๐จ๐ญ ๐ฃ๐ฎ๐ฌ๐ญ ๐ญ๐ก๐ ๐ฌ๐ข๐ ๐ง๐ข๐ง๐ ๐จ๐ ๐ ๐๐จ๐ซ๐ฆ. ๐๐ง๐๐จ๐ซ๐ฆ๐๐ ๐๐จ๐ง๐ฌ๐๐ง๐ญ ๐ข๐ฌ ๐๐๐จ๐ฎ๐ญ ๐ ๐ญ๐ก๐จ๐ซ๐จ๐ฎ๐ ๐ก ๐ฉ๐ซ๐จ๐๐๐ฌ๐ฌ ๐จ๐ ๐๐จ๐ฆ๐ฆ๐ฎ๐ง๐ข๐๐๐ญ๐ข๐จ๐ง ๐๐๐ญ๐ฐ๐๐๐ง ๐ฉ๐๐ญ๐ข๐๐ง๐ญ ๐๐ง๐ ๐ฉ๐ซ๐จ๐ฏ๐ข๐๐๐ซ.” โ๐๐ซ. ๐๐๐ซ๐จ๐ง ๐ ๐ข๐ง๐คย If a patient consents to a physician’s 3rd choice for treatment, rather than his first two preferences, does that consent operate as an instruction telling the physician to proceed with the consented treatment? Can a physician refuse a treatment, because it is not his first or second choice?
Yes, that consent operates as an instruction to proceed with that specific option, but only if the physician still considers it a medically appropriate choice. A physician can refuse to provide a treatment if they believe it falls below the standard of care, but they cannot refuse a treatment simply because it was not their personal first or second preference.
The Dynamics of Selecting a 3rd-Choice Treatment
The Scope of Instruction: When a physician presents three viable medical options, they are confirming that all three options fit within the boundaries of acceptable medical practice. By selecting the third choice, the patient is instructing the doctor: “Of the acceptable paths you offered, this is the only one I authorize you to perform.”
The Limit of the Instruction: The patientโs choice does not force the doctor to perform the procedure blindly. If the patient’s medical condition changes rapidly and makes the third choice dangerous or ineffective, the physician’s professional obligation requires them to halt and re-evaluate.
Why a Physician Cannot Refuse Simply Over “Preferences”
The Offered Options Rule: If a physician offers a treatment as a viable option, they have already validated it as a medically sound choice. Refusing to perform it simply because the patient didn’t pick Option 1 or Option 2 is a violation of the shared decision-making process.
The Threshold of Refusal: A physician can only legally and ethically refuse a treatment if it is medically futile, violates their professional judgment, falls outside their scope of competence, or if they have a profound moral/conscientious objection (which must be declared upfront, with the patient safely transferred to another provider).
Patient Autonomy Controls the Choice: In medicine, the physicianโs role is to establish the boundary of what is medically safe and effective. Within that safe boundary, the patientโs values, lifestyle, and preferences dictate which option is chosen.
๐๐ก๐ ๐๐๐ ๐๐ซ๐ฎ๐ ๐ ๐ซ๐๐ฏ๐๐ฒ๐๐ซ๐ ๐ข๐ฌ ๐๐ซ๐จ๐ฐ๐๐๐
Posted by Michael A. S. Guth on August 5th, 2026
Since 1995, when the FDA approved riluzole for amyotrophic lateral sclerosis (ALS) โ offering a median survival extension measured in weeks โ more than 60 compounds have advanced to clinical evaluation, with the overwhelming majority failing to demonstrate efficacy.(p1) It is worth distinguishing, within that graveyard, between uninformative โfailedโ trials that lacked biomarkers and left little beyond a null clinical result, and โnegativeโ trials that incorporated biomarkers and therefore still yielded interpretable mechanistic information even without clinical benefit.
The most recent casualty is instructive. In September 2022, the FDA granted accelerated approval to AMX0035 (sodium phenylbutyrate-taurursodiol) after the Phase II CENTAUR trial demonstrated a 25% attenuation in ALS Functional Rating Scale-Revised (ALSFRS-R) decline.(p2),(p3)ย However, in March 2024, the blinded Phase III PHOENIX trial reported a primary end point p-value of 0.667 โ indicating no difference from placebo (https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-topline-results-from-global-phase-3-phoenix-trial-of-amx0035-in-als) โ prompting Amylyx Pharmaceuticals to voluntarily withdraw the product from the market (https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-formal-intention-to-remove-relyvrior/albriozatm-from-the-market-provides-updates-on-access-to-therapy-pipeline-corporate-restructuring-and-strategy).(p4)ย CENTAUR/PHOENIX is a good example of the โnegative but informativeโ category: the blinded failure mechanistically clarified the fragility of open-label ALSFRS-R signals, even though it was a clinical disappointment.
The therapeutic arithmetic is unforgiving. Riluzole and edaravone offer only modest slowing of disease progression. Tofersenโs 2023 accelerated approval for SOD1-ALS represents a genuine precision medicine advance, but it applies to fewer than 2% of all ALS patients.(p5)ย For the remaining 98% โ the overwhelming majority with sporadic TAR DNA-binding protein 43 (TDP-43) proteinopathy โ no approved therapy stops or reverses neurodegeneration. Median survival from symptom onset remains 24 to 48ย months.
Into this landscape arrives CTx1000, an adeno-associated virus serotype 9 (AAV9)-based gene therapy developed by Celosia Therapeutics, a Macquarie University (Australia) spin-out. AAV9 was selected primarily for its efficient transduction of neurons and glia, not simply for its capacity to cross the bloodโbrain barrier. CTx1000 is currently known only by this code name and does not yet have a generic name or an approved commercial brand name.
Foustย et al.ย demonstrated that AAV9 transduction is markedly age-dependent: intravascular delivery in neonatal animals transduces motor neurons and dorsal root ganglia efficiently, whereas in adult animals the same route shifts toward predominantly astrocytic transduction with comparatively limited neuronal uptake.(p6) This is a material caveat for ALS, a disease of mid-to-late adult life, and for KOANEWAโs intracisternal magna (ICM) delivery route specifically, which was chosen to improve neuronal and glial distribution relative to peripheral intravenous dosing. In early 2026, Celosia dosed its first patient in the KOANEWA Phase Ib trial of CTx1000, which uses a 14-3-3ฮธ fusion degron protein to selectively target pathological TDP-43.
๐๐๐ซ๐ ๐๐ญ๐ข๐ง๐ ๐๐๐-๐๐ ๐ข๐ง ๐๐๐: ๐๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ ๐ก๐ฎ๐ซ๐๐ฅ๐๐ฌ, ๐ญ๐ซ๐ข๐๐ฅ ๐๐๐ฌ๐ข๐ ๐ง ๐๐๐๐ข๐๐ข๐๐ง๐๐ข๐๐ฌ, ๐๐ง๐ ๐ญ๐ก๐ ๐๐๐ฎ๐ฌ๐๐ฅ ๐๐ฏ๐ข๐๐๐ง๐๐ ๐ ๐๐ฉ ๐๐จ๐ซ ๐๐๐ฑ๐๐๐๐
Posted by Michael A. S. Guth on August 5th, 2026
๐๐๐ซ๐ ๐๐ญ๐ข๐ง๐ ๐๐๐-๐๐ ๐ข๐ง ๐๐๐: ๐๐๐ ๐ฎ๐ฅ๐๐ญ๐จ๐ซ๐ฒ ๐ก๐ฎ๐ซ๐๐ฅ๐๐ฌ, ๐ญ๐ซ๐ข๐๐ฅ ๐๐๐ฌ๐ข๐ ๐ง ๐๐๐๐ข๐๐ข๐๐ง๐๐ข๐๐ฌ, ๐๐ง๐ ๐ญ๐ก๐ ๐๐๐ฎ๐ฌ๐๐ฅ ๐๐ฏ๐ข๐๐๐ง๐๐ ๐ ๐๐ฉ ๐๐จ๐ซ ๐๐๐ฑ๐๐๐๐, Michael A.S. Guth,
Drug Discovery Today, Volume 31, Issue 5, 2026, 104752, ISSN 1359-6446,
https://doi.org/10.1016/j.drudis.2026.104752.
https://www.sciencedirect.com/science/article/pii/S1359644626001571
Highlights
โข Over 60 amyotrophic lateral sclerosis (ALS) drug failures since 1995 underscore a persistent trial graveyard.
โข CTX1000โs degron fusion selectively clears toxic cytoplasmic TDP-43 โ in mice.
โข The open-label KOANEWA trial lacks a control arm and validated biomarkers.
โข Moving to Phase III without a TDP-43 biomarker risks replicating past failures.
โข CTX1000 and VTx-002 parallel trials will together settle the TDP-43 causal architecture.
The therapeutic landscape for amyotrophic lateral sclerosis (ALS) has been characterized by decades of clinical trial failures, often attributed to biological heterogeneity, end-point insensitivity, and a profound evidence gap regarding target engagement. With TAR DNA-binding protein 43 (TDP-43) aggregation emerging as a hallmark feature in the vast majority of ALS cases, new precision-medicine modalities โ most notably the proteolysis-targeting chimera (PROTAC) CTx1000 โ aim to address the underlying causal pathology through selective degradation of mislocalized TDP-43. This review critically evaluates the regulatory hurdles and trial design deficiencies that have historically undermined ALS clinical development, and incorporates the dual sequestration hypothesis as a framework to interpret the convergence of TDP-43 pathology across neurodegenerative diseases. It concludes that it is imperative that the field adopts more rigorous biomarker-led methodologies, and that although target-specific degraders offer a sophisticated technological leap, their success depends on addressing fundamental knowledge gaps in target engagement, age-dependent vector tropism, and trial design architecture.
While the science sounds futuristic, bringing these treatments into everyday hospitals requires solving major engineering and logistical puzzles. Because alpha particles pack an incredible punch over a tiny microscopic distance, handling them safely demands specialized shielding, strict facility guidelines, and meticulous tracking from the moment they are manufactured. Ensuring the safety of both hospital staff and patients is the absolute top priority before these therapies can become widely available.
One of the biggest challenges in this field is making sure the radioactive medicine stays exactly where it is supposed to be inside the body. Advanced safety protocols and specialized molecular carriers are designed to lock the radioactive atoms in place, preventing them from wandering off into healthy organs. This precision engineering is what separates targeted radiation from traditional, broader treatments that often cause widespread side effects.
Translating these complex therapies into routine clinical care takes a massive team effort involving doctors, physicists, pharmacists, and safety experts working hand in hand. Every single hospital workflowโfrom preparation to administration and waste disposalโmust be carefully mapped out and rehearsed. Building this robust infrastructure is the key to transforming experimental breakthroughs into reliable, mainstream medical options.
My latest peer-reviewed, PubMed-indexed paper detailing a comprehensive safety framework for implementing Lead-212-targeted alpha therapy is now officially published and openly available in Clinical Nuclear Medicine Open. This work represents a vital step toward making advanced radiopharmaceuticals safer and more accessible for the patients who need them most. Anyone interested in the future of cancer care should read the full article and join the conversation.